Olga Lopez
Medical · Homestead, FLNPI 1679603237
Payments from drug & device makers
Across 117 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$619
- AbbVie$283
- Amgen$236
- Novo Nordisk$169
- Pfizer$166
- Exact Sciences$164
- plus $600 from 14 others
What the payments were for
- Food & beverage$2,238100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 45 | $619 |
| AbbVie | 15 | $283 |
| Amgen(2 entities) | 4 | $236 |
| Novo Nordisk | 8 | $169 |
| Pfizer | 8 | $166 |
| Exact Sciences | 7 | $164 |
| GSK | 7 | $158 |
| AstraZeneca | 7 | $140 |
| Eisai Inc. | 3 | $57 |
| Bayer | 2 | $39 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| Abbott | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Philips North America LLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PENNSAID$185
How this compares
$2,238 in reported general payments places this provider in the 70th percentile of 2,031 medical providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $42,917 |
| OzempicSemaglutide | 23 | $21,840 |
| MounjaroTirzepatide | 16 | $16,682 |
| TrulicityDulaglutide | 11 | $9,974 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,244 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,866 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,270 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 32 | $949 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $812 |
| Levothyroxine Sodium | 78 | $770 |
| Omeprazole | 36 | $580 |
| Gabapentin | 51 | $561 |
| Atorvastatin Calcium | 73 | $537 |
| Losartan Potassium | 59 | $525 |
| Diclofenac Sodium | 31 | $508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $619 | $26,65627 claims |
| Novo NordiskOzempic | $169 | $21,84023 claims |
| GSKBreo Ellipta | $158 | $4,24411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,031 medical providers in Florida.
Other medical in Homestead
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
- Kathleen TrummerWellington$166K
- Sandra SnyderTampa$156K
- Francine PhillipsLand O Lakes$145K
- Chelsie FerrellDeland$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.